Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Panobinostat MeSH Descriptor Data 2025


MeSH Heading
Panobinostat
Tree Number(s)
D02.092.570.394.535
D02.241.511.372.535
D03.633.100.473.746
Unique ID
D000077767
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000077767
Scope Note
An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.
Entry Term(s)
Farydak
LBH 589
LBH589
NVP-LBH589
Pharm Action
Antineoplastic Agents
Histone Deacetylase Inhibitors
Registry Numbers
9647FM7Y3Z
0
CAS Type 1 Name
2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino) methyl)phenyl)-, (2E)-
Public MeSH Note
2019; PANOBINOSTAT was indexed under HYDROXAMIC ACIDS and INDOLES 2005-2018
History Note
2019 (2005)
Date Established
2019/01/01
Date of Entry
2018/07/09
Revision Date
2018/05/21
Panobinostat Preferred
LBH589 Narrower
Farydak Narrower
page delivered in 0.171s